- Methedrone
- 4-MeOMC
- 4-Methoxymethcathinone
- PMMA-βk
- PMMC
- PM-MCAT
- Para-methoxymethcathinone
- bk-PMMA
Archer, RP. Fluoromethcathinone, a new substance of abuse. Forensic Sci. Int., 1 Jan 2009, 185 (1–3), 10–20. 1.4 MB. https://doi.org/10.1016/j.forsciint.2008.11.013 GC,MS,NMR,IR
Iversen, LL. Consideration of the cathinones, Advisory Council on the Misuse of Drugs, 31 Mar 2010. 286 kB.
Jankovics, P; Váradi, A; Tõlgyesi, L; Lohner, S; Németh-Palotás, J; Kőszegi-Szalai, H. Identification and characterization of the new designer drug 4′-methylethcathinone (4-MEC) and elaboration of a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) screening method for seven different methcathinone analogs. Forensic Sci. Int., 15 Jul 2011, 210 (1–3), 213–220. 899 kB. https://doi.org/10.1016/j.forsciint.2011.03.019 #6 MS,NMR,IR,UV
Tsujikawa, K; Mikuma, T; Kuwayama, K; Miyaguchi, H; Kanamori, T; Iwata, YT; Inoue, H. Degradation pathways of 4-methylmethcathinone in alkaline solution and stability of methcathinone analogs in various pH solutions. Forensic Sci. Int., 10 Jul 2012, 220 (1–3), 103–110. 671 kB. https://doi.org/10.1016/j.forsciint.2012.02.005
Toole, KE; Fu, S; Shimmon, RG; Kraymen, M; Taflaga, S. Color tests for the preliminary identification of methcathinone and analogues of methcathinone. Microgram J., 1 Jan 2012, 9 (1), 27–32. 496 kB.
Zuba, D. Identification of cathinones and other active components of ‘legal highs’ by mass spectrometric methods. Trends Anal. Chem., 1 Feb 2012, 32, 15–30. 576 kB. https://doi.org/10.1016/j.trac.2011.09.009
Zuba, D; Byrska, B. Prevalence and co-existence of active components of ‘legal highs’. Drug Test. Anal., 1 Jun 2013, 5 (6), 420–429. 1.3 MB. https://doi.org/10.1002/dta.1365
Prosser, JM; Nelson, LS. The toxicology of bath salts: a review of synthetic cathinones. J. Med. Toxicol., 1 Nov 2011, 8 (1), 33–22. 267 kB. https://doi.org/10.1007/s13181-011-0193-z
Glennon, RA. Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv. Pharmacol., 1 Jan 2014, 69, 581–620. 564 kB. https://doi.org/10.1016/B978-0-12-420118-7.00015-9
Hyperlab. Hyperlab new compounds. 29 Sep 2014. 232 kB. Note: Contains links to hyperlab.info that require elevated access/karma to follow.
Clark, CR. Synthesis and analytical profiles for regioisomeric and isobaric amines related to MDMA, MDEA and MBDB: Differentiation of drug and non-drug substances of mass spectral equivalence, US DOJ, 1 Oct 2011. 3.9 MB. #2.1-3
Bonano, JS; Banks, ML; Kolanos, R; Sakloth, F; Barnier, ML; Glennon, RA; Cozzi, NV; Partilla, JS; Baumann, MH; Negus, SS. Quantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues: QSAR of para-substituted methcathinone analogues. Br. J. Pharmacol., 1 May 2015, 172 (10), 2433-2444. 985 kB. https://doi.org/10.1111/bph.13030 #4-OCH3 MCAT
Gwak, S; Arroyo-Mora, LE; Almirall, JR. Qualitative analysis of seized synthetic cannabinoids and synthetic cathinones by gas chromatography triple quadrupole tandem mass spectrometry. Drug Test. Anal., 1 Feb 2015, 7 (2), 121-130. 1.1 MB. https://doi.org/10.1002/dta.1667 #5
Kavanagh, PV; Power, JD. New psychoactive substances legislation in Ireland – Perspectives from academia. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 884-891. 1.2 MB. https://doi.org/10.1002/dta.1598
Fornal, E. Study of collision-induced dissociation of electrospray-generated protonated cathinones. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 705-715. 527 kB. https://doi.org/10.1002/dta.1573 #9
Mas-Morey, P; Visser, MHM; Winkelmolen, L; Touw, DJ. Clinical Toxicology and Management of Intoxications With Synthetic Cathinones ("Bath Salts"). J. Pharm. Pract., 25 Nov 2012, 26 (4), 353-357. 312 kB. https://doi.org/10.1177/0897190012465949
Suzuki, J; Moriyasu, T; Nagashima, M; Kanai, C; Shimizu, M; Hamano, T; Nagayama, T. Analysis of uncontrolled drugs purchased in the fiscal year 2009. Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2010, 61 163–172. 971 kB. #4-Methoxymethcathinone LC,MS,NMR
EMCDDA. New drugs in Europe, 2009, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2010. 321 kB. #17
McLaughlin, G; Morris, N; Kavanagh, PV; Power, JD; Dowling, G; Twamley, B; O’Brien, J; Talbot, B; Walther, D; Partilla, JS; Baumann, MH; Brandt, SD. Synthesis, characterization and monoamine transporter activity of the new psychoactive substance mexedrone and its N-methoxy positional isomer, N-methoxymephedrone. Drug Test. Anal., 1 Mar 2017, 9 (3), 358-368. 7.1 MB. https://doi.org/10.1002/dta.2053 GC,LC,MS,NMR,other
Simmons, SJ; Leyrer-Jackson, JM; Oliver, CF; Hicks, C; Muschamp, JW; Rawls, SM; Olive, MF. DARK classics in chemical neuroscience: Cathinone-derived psychostimulants. ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2379–2394. 1.6 MB. https://doi.org/10.1021/acschemneuro.8b00147 #Methedrone
Baumann, MH; Walters, HM; Niello, M; Sitte, HH. Neuropharmacology of synthetic cathinones. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 113–142. 409 kB. https://doi.org/10.1007/164_2018_178 #4-Methoxy MCAT
Kronstrand, R; Guerrieri, D; Vikingsson, S; Wohlfarth, A; Gréen, H. Fatal poisonings associated with new psychoactive substances. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 495–541. 477 kB. https://doi.org/10.1007/164_2018_110 #Methedrone
Kraemer, M; Boehmer, A; Madea, B; Maas, A. Death cases involving certain new psychoactive substances: A review of the literature. Forensic Sci. Int., 1 May 2019, 298, 186–267. 6.7 MB. https://doi.org/10.1016/j.forsciint.2019.02.021 #Methedrone
Walther, D; Shalabi, AR; Baumann, MH; Glennon, RA. Systematic structure–activity studies on selected 2-, 3-, and 4-monosubstituted synthetic methcathinone analogs as monoamine transporter releasing agents. ACS Chem. Neurosci., 16 Jan 2019, 10 (1), 740–745. 498 kB. https://doi.org/10.1021/acschemneuro.8b00524 #4d NMR,other
Bork, W; Dahlenburg, R; Gimbel, M; Jacobsen-Bauer, A; Zörntlein, S. Herleitung Von Grenzwerten Der „nicht Geringen Menge“ Im Sinne Des Btmg. Toxichem Krimtech, 1 Jan 2019, 86 (1), 5–91. 4.4 MB. #CA-022
Hägele, JS; Basrak, M; Schmid, MG. Enantioselective separation of novel psychoactive substances using a Lux® AMP 3 μm column and HPLC-UV. J. Pharm. Biomed. Anal., 5 Feb 2020, 179, 112967. 3.6 MB. https://doi.org/10.1016/j.jpba.2019.112967 #P4 LC
Clancy, L; Philp, M; Shimmon, R; Fu, S. Development and validation of a color spot test method for the presumptive detection of 25-NBOMe compounds. Drug Test. Anal., 19 Aug 2020, 13 (5), 929-943. 11.3 MB. https://doi.org/10.1002/dta.2905 #4-methoxymethcathinone
Simmler, LD; Rickli, A; Hoener, MC; Liechti, ME. Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology, 1 Apr 2014, 79, 152–160. 787 kB. https://doi.org/10.1016/j.neuropharm.2013.11.008 #Methedrone
Philp, M; Shimmon, R; Stojanovska, N; Tahtouh, M; Fu, S. Development and validation of a presumptive colour spot test method for the detection of piperazine analogues in seized illicit materials. Anal. Methods, 1 Jan 2013, 5 (20), 5402. 783 kB. https://doi.org/10.1039/c3ay40511g #4-Methoxymethcathinone MS,NMR,IR,spot